The Omeros Corporation, a biopharmaceutical company headquartered in Seattle, Washington, operates within the Health Care sector, specifically in the Pharmaceuticals industry. Listed on the Nasdaq under the ticker symbol OMRS, Omeros Corp. is engaged in the development of a diverse pipeline of product candidates across various medical fields, including orthopedics, rheumatology, urology, cardiovascular medicine, general surgery, and pain management.
As of the close of trading on December 31, 2025, Omeros Corp. recorded a closing price of $13.53. This figure represents a notable decline from the company’s 52-week high of $17.65, achieved on December 23, 2025. Conversely, the 52-week low was observed at $2.95 on June 30, 2025. This price trajectory indicates a significant contraction of approximately 23.5% from the year’s peak to the most recent closing price.
The market capitalization of Omeros Corp. stands at approximately $959,283,258 USD, reflecting its valuation in the market. The price movement over the past year suggests a period of limited volatility in recent trading sessions, as evidenced by the narrow range between the recent low and high. However, the steep decline from the peak price to the current level highlights a period of notable price compression.
Despite the fluctuations in stock price, there has been a lack of recent news beyond the December 31, 2025, headline, suggesting that the recent market activity has not been driven by new public disclosures. This absence of new information may contribute to the observed market behavior, as investors react to the existing data and market conditions.
In summary, Omeros Corp. continues to focus on its strategic initiatives within the pharmaceutical sector, despite the recent challenges reflected in its stock performance. The company’s commitment to developing innovative medical solutions across various therapeutic areas remains a key aspect of its operational strategy.
